Companies looking to bring the first CAR-T treatment for autoimmune diseases to market will present their latest data at the European Alliance of Associations for Rheumatology (EULAR) meeting this week.
Biotechs Vie To Take The Lead In Autoimmune CAR-Ts
First clinical efficacy readouts from several biotech companies developing CAR-Ts for systemic lupus erythematosus will be unveiled at EULAR, though the level of competition may be unsustainable.
More from Clinical Trials
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from R&D
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.